FT516

Generic Name
FT516
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
-
Background

FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation. FT516 is currently being tested agains...

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

First Posted Date
2020-09-16
Last Posted Date
2023-09-21
Lead Sponsor
Fate Therapeutics
Target Recruit Count
12
Registration Number
NCT04551885
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

๐Ÿ‡บ๐Ÿ‡ธ

MD Anderson Cancer Center, Houston, Texas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Hackensack University Medical Center/John Theurer Cancer Center, Hackensack, New Jersey, United States

Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia

Phase 1
Completed
Conditions
COVID-19
Interventions
Drug: FT516
First Posted Date
2020-04-27
Last Posted Date
2022-04-05
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
5
Registration Number
NCT04363346
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Minnesota, Minneapolis, Minnesota, United States

FT516 in Subjects With Advanced Hematologic Malignancies

First Posted Date
2019-07-17
Last Posted Date
2023-10-26
Lead Sponsor
Fate Therapeutics
Target Recruit Count
72
Registration Number
NCT04023071
Locations
๐Ÿ‡บ๐Ÿ‡ธ

MD Anderson Cancer Center, Houston, Texas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Swedish Cancer Institute, Seattle, Washington, United States

๐Ÿ‡บ๐Ÿ‡ธ

Mayo Clinic, Phoenix, Arizona, United States

and more 4 locations
ยฉ Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy